"10.1371_journal.pone.0052229","plos one","2012-12-28T00:00:00Z","Alexander Michael Labeit; Jens Klotsche; Lars Pieper; David Pittrow; Franziska Einsle; GÃ¼nter Karl Stalla; Hendrik Lehnert; Sigmund Silber; Andreas Michael Zeiher; Winfried MÃ¤rz; Martin Wehling; Hans-Ulrich Wittchen","Clinical Pharmacology Mannheim, Institute of Experimental and Clinical Pharmacology and Toxicology, Medical Faculty Mannheim of the University of Heidelberg, Heidelberg, Germany; Department of Health Sciences, University of Leicester, Leicester, United Kingdom; Institute of Clinical Psychology and Psychotherapy and Center of Clinical Epidemiology and Longitudinal Studies, TU Dresden, Dresden, Germany; Max Planck Institute of Psychiatry, Munich, Germany; Department of Internal Medicine I, University of LÃ¼beck, LÃ¼beck, Germany; Private Cardiology Practice and Clinic, Munich, Germany; Department of Internal Medicine III, Cardiology, Goethe-University Frankfurt, Frankfurt, Germany; Synlab Academy, Synlab Services GmbH, Mannheim, Germany; Mannheim Institute of Public Health, Rupertus Carola University of Heidelberg, Medical Faculty Mannheim, Mannheim, Germany; Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria","Conceived and designed the experiments: HL GS AZ WM DP SS MW. Performed the experiments: HL GS AZ WM DP SS MW. Analyzed the data: AL JK LP. Contributed reagents/materials/analysis tools: AL JK LP. Wrote the paper: AL JK LP DP FE GS HL SS AZ WM MW HW.","The authors have read the journalâ€™s policy and have the following conflicts: Alexander Michael Labeit, Jens Klotsche, Lars Pieper, David Pittrow, Franziska Einsle, GÃ¼nter Karl Stalla, Hendrik Lehnert, Andreas Michael Zeiher, Hans-Ulrich Wittchen: none. Sigmund Silber: The author served as an advisor or consultant for Abbott Laboratories, Boston Scientific, Medtronic. Martin Wehling: The author was employed by AstraZeneca R&D, MÃ¶lndal, as director of discovery medicine (translational medicine) from 2003â€2006, while on sabbatical leave from his professorship at the University of Heidelberg. After return to this position in January 2007, he receives lecturing and consulting fees from Sanofi-Aventis, Novartis, Takeda, Roche, Pfizer, Bristol-Myers, Daichii-Sankyo, Lilly and Novo-Nordisk. This does not alter the authorsâ€™ adherence to all the PLOS ONE policies on sharing data and materials. Winfried MÃ¤rz is affiliated with Synlab Academy, Synlab Services GmbH, Mannheim, Germany, though it has no bearing on this manuscript. This does not alter the authorsâ€™ adherence to all the PLOS ONE policies on sharing data and materials.","2012","12","Alexander Michael Labeit","AML",12,TRUE,7,7,3,12,TRUE,TRUE,FALSE,0,NA,FALSE
